Anti-tumor activity and prolonged patient survival were noted in the combination arm of primarily ICB-resistant patients, suggesting benefit from the combination of PRGN-2009, the PD-L1 ICB, and TGF-β inhibition. This evidence concerns the gene TGFB1 and neoplasm.